Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.

Brody Winn  
*Rhode Island Hospital, Alpert Medical School*

Rosemarie Tavares  
*Rhode Island Hospital, Alpert Medical School*

Andres Matoso  
*Rhode Island Hospital, Alpert Medical School*

Lelia Noble  
*Rhode Island Hospital, Alpert Medical School*

Jacqueline Fanion  
*Rhode Island Hospital, Alpert Medical School*

See next page for additional authors

**Recommended Citation**

Winn, Brody; Tavares, Rosemarie; Matoso, Andres; Noble, Lelia; Fanion, Jacqueline; Waldman, Scott A; and Resnick, Murray B, "Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas." (2010). *Department of Pharmacology and Experimental Therapeutics Faculty Papers*. Paper 2.

https://jdc.jefferson.edu/petfp/2

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Brody Winn, Rosemarie Tavares, Andres Matoso, Lelia Noble, Jacqueline Fanion, Scott A Waldman, and Murray B Resnick

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/petfp/2
As submitted to:

*Human Pathology*

And later published as:

“Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas”

*Human Pathology*

**Volume 41, Issue 1, January 2010, Pages 123-128**

DOI: 10.1016/j.humpath.2009.07.009

Brody Winn, MD\textsuperscript{a}; Rosemarie Tavares, BSc\textsuperscript{a}; Andres Matoso, MD\textsuperscript{a}; Lelia Noble\textsuperscript{a};

Jacqueline Fanion MSc\textsuperscript{a}; Scott A. Waldman, MD, PhD\textsuperscript{b} and Murray B. Resnick, MD, PhD\textsuperscript{a}.

\textsuperscript{a}Department of Pathology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI

\textsuperscript{b}Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
Corresponding Author:
Murray Resnick, MD, PhD
Rhode Island Hospital
Dept. of Pathology
APC 12-111
593 Eddy Street
Providence, RI 02903
T: 401 444-4380
F: 401 444-8514
mresnick@lifespan.org

Running Title:
GCC in Colon Carcinomas
Abstract

Guanylyl cyclase C (GCC) a receptor for bacterial diarrheagenic enterotoxins is expressed selectively by intestinal epithelium and is an endogenous downstream target of CDX2. The expression of GCC is preserved throughout the adenoma/carcinoma sequence in the colorectum. Detection of GCC expression by RT-PCR is currently being validated as a technique to identify occult lymph node metastases in patients with colorectal cancer (CRC) and for circulating cells in the blood for postoperative surveillance. Although GCC is widely expressed by well-differentiated CRC its expression in poorly differentiated CRC has not been evaluated. A tissue microarray was created from 72 archival specimens including 44 poorly differentiated (PDC), 15 undifferentiated or medullary (MC), 10 signet ring cell (SRC) and 3 neuroendocrine (NE) CRCs. Matched normal colonic mucosa was used as a positive control. Immunohistochemical staining for GCC and CDX2 was evaluated as positive or negative based on at least a 10% extent of staining. Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC and NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets
were positive for CDX2 respectively. There was excellent correlation between GCC and CDX2 expression on a case by case basis (p<0.0001). Immunopositivity for GCC was greater than 95% in a separately stained microarray series of well/moderately differentiated CRCs. In conclusion, GCC expression is lost in a quarter of poorly differentiated and half of undifferentiated CRC. Therefore the utility of GCC expression as a diagnostic and prognostic marker for CRC may be questionable in poorly differentiated colorectal neoplasms.

**Key Words**: Guanylyl cyclase C; Poorly differentiated; Colon; Carcinoma; CDX2

**Introduction**

Colorectal carcinoma (CRC) is the third most common cause of cancer death in the United States.\(^1\) CRC can be divided into well, moderately and poorly differentiated adenocarcinomas based on the histologic presence of glandular differentiation. By definition CRC is classified as being poorly differentiated (or high grade) if more than 50% of the tumor is formed by non-gland forming neoplastic cells.\(^2\) Subtypes of poorly differentiated CRCs include undifferentiated or medullary carcinomas (MC), signet ring cell carcinomas (SRC), neuroendocrine carcinomas (NE) and poorly differentiated not otherwise specified (PDC).\(^2\) Approximately 20% of all CRC fall into the poorly differentiated category.\(^3\)

A number of immunohistochemical and PCR markers specific for intestinal epithelium have been characterized and their retention in many CRCs has been utilized for the identification of metastatic tumors, detection of occult lymph node metastases and
for detecting circulating tumor cells in the peripheral blood.\textsuperscript{4-6} Guanylyl cyclase C (GCC) is an N-linked glycoprotein receptor for heat stable enterotoxin that is expressed by intestinal epithelium.\textsuperscript{7,8} The intestine specific expression of the GCC promoter requires CDX2.\textsuperscript{9} GCC has been shown to be a sensitive and specific marker for CRCs, and its expression is retained in the adenoma to adenocarcinoma sequence.\textsuperscript{10,11} Molecular studies to detect the presence of GCC have been proposed as a method of detecting occult micrometastases to regional lymph nodes in CRCs.\textsuperscript{12-15} To date, the expression of GCC in poorly differentiated CRCs has not been thoroughly investigated.

CDX2 is a transcription factor expressed in intestinal epithelial cells and is thought to play a role in the differentiation and proliferation of intestinal epithelium.\textsuperscript{16} Several studies have show CDX2 to be both a sensitive and specific marker of intestinal differentiation; furthermore, it appears to be overexpressed in CRC tumor cells compared with normal intestinal epithelium.\textsuperscript{17-19} While the majority of well and moderately differentiated CRCs stain strongly for CDX2, certain studies have shown that a lower proportion of poorly differentiated tumors express CDX2.\textsuperscript{20-21}

The focus of this study was to examine the pattern of staining of GCC expression in a large cohort of poorly differentiated CRCs and to correlate these findings with the expression of CDX2.

\textbf{Material and Methods}

\textbf{Patients and samples}

Formalin-fixed paraffin embedded tissues from 72 specimens including 44 poorly differentiated (PDC), 15 undifferentiated or medullary (MC), 10 signet ring cell (SRC)
and 3 neuroendocrine (NE) CRCs were collected from the archives of the Department of Pathology at the Rhode Island and Miriam Hospitals in accordance with Institutional Review Board approvals from both hospitals. The written reports of all colon cancer patients diagnosed between the years 1984-2008 were reviewed and all cases classified as PDC, MC, SRC and NE were selected. Histological sections were reviewed by MR and BW and were reclassified based on the current WHO criteria.²

**Tissue microarray construction**

Areas of pure invasive carcinoma were identified on hematoxylin-eosin-stained slides from each case. In cases of PDC that showed focal well differentiated areas, only the poorly differentiated components were selected. The corresponding areas on the paraffin embedded source blocks were identified and marked. The source blocks were then cored and a 1-mm core was transferred to the “master block” using the Beecher Tissue Microarrayer (Beecher Instruments, Silver Spring, MD). Approximately three to five tissue cores of tumor were obtained for each case. Additionally, two to three cores of histologically normal adjacent colonic mucosal tissue were obtained and arrayed in the same manner. Whole sections of five cases of PDC which had focal well differentiated areas were also assessed. In addition a tissue microarray (TMA) constructed previously containing 111 cases of primarily moderately to well differentiated CRC was assessed.²²

**Immunohistochemistry**

Immunohistochemical staining for each antigen was performed on 6 micron paraffin sections of each of the TMA masterblocks. The TMA sections were stained for
CDX2 (mouse antibody, clone CDX2-88, 1:50, Biogenex, San Ramon, CA) and GCC (rabbit polyclonal, Gift from SA Waldman, first described by Birbe et al\textsuperscript{11}) were performed using the Dako Autostainer with the Dako Envision Plus kit or manually with the Dako Envision Plus kit. The slides were counter stained with hematoxylin and dehydrated in graded alcohols through to xylene and coverslipped. Normal colonic mucosa served as a positive control both CDX2 and GCC.

**Immunohistochemical assessment**

The immunohistochemical stains were scored using a two-tiered scoring system: positive or negative. A positive score required moderate to strong staining of more than 10\% of the tumor cell population, whereas a negative score included tumors with focal (less than 10\%) or weak staining. This cutoff was reached based on personal experience and allowed for minimal interobserver variability in the scoring. BW and MR independently scored each of the sections without knowledge of the histologic diagnosis or staining pattern with the other marker. There was a high correlation between the two scores and in the few discrepant cases, a consensus was reached after joint review.

**Statistical analysis**

Staining for GCC and CDX2 was compared between well differentiated CRCs and PDC, MC, SRC and NE using Fischer’s exact test. Correlation between GCC staining and CDX2 staining and the clinicopathologic comparison of MC and PDC was also analyzed using Fischer’s exact test. Two-tailed P values of 0.05 or less were considered to be statistically significant.
Results

The clinicopathologic characteristics of the 72 cases of CRC are summarized in Table 1. The MC group had the highest mean age at the time of surgery (76yrs) as compared to the SRC, PDC and NE groups which were 71yrs, 68yrs and 62yrs respectively. The majority of patients with MC (87%), SRC (80%) and NE (67%) were female whereas only 45% of patients with PDC were female. The majority of tumors occurred on the right side in the MC (73%), SRC (80%) and NE (67%) groups whereas PDC was right sided in only 45% of cases.

An example of each of the tumor types studied, PDC, MC, SRC and NE is shown in Figure 1. MC lacked glandular differentiation and exhibited solid sheets of neoplastic cells with a syncytial growth pattern and a moderate amount of eosinophilic cytoplasm. An intra-tumoral and peri-tumoral lymphocytic infiltrate was present. The PDC tumors were composed of at least 50% solid sheets or single neoplastic cells. Typically the tumor cells were more pleomorphic than the MC group. SRC were composed of at least 50% of cells with prominent cytoplasmic mucin and characteristic displacement of the nucleus. NE exhibited a typical neuroendocrine H&E appearance in combination with strong positivity for at least one neuroendocrine marker.

The normal colonic epithelium served as a positive control for GCC and showed typical apical membranous staining in all cases examined (Figure 2A). GCC stained the apical luminal membrane of the tumor cells in the well to moderately differentiated tumors (Figure 2B), whereas a predominantly cytoplasmic staining pattern was seen in the more poorly differentiated areas, which was most pronounced in the MC group.
(Figure 2C, 2D). The SRC tumors exhibited a cytoplasmic with focal membranous staining (Figure 2E). NE tumors showed cytoplasmic and membranous staining (Figure 2F). The pattern of CDX2 staining was nuclear in both the tumor cells and the normal colonic epithelium.

Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC and NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets were positive for CDX2 (Table 2). In contrast all but two of the 111 moderately to well differentiated cases examined stained strongly for both GCC and CDX2. There was excellent correlation between GCC and CDX2 expression on a case per case basis (p<0.0001). GCC staining was more commonly lost in MC as compared to PDC (p=0.025). Several separately stained whole sections from five tumors showing areas of both well and poorly differentiated components were also examined. Positive GCC staining in the well-differentiated component and negative staining in the poorly differentiated areas was seen in these cases as depicted in Figure 3.

**Discussion**

GCC has been shown to be both a specific and sensitive marker of intestinal differentiation and is being investigated as a biomarker for occult lymph node metastases and circulating peripheral tumor cells.\textsuperscript{10-15} While essentially all well or moderately differentiated CRCs have been shown to stain positively with GCC there is only limited data on expression of GCC in PDC.\textsuperscript{10,11,14} Birbe et al. showed positive GCC staining in 10 out of 10 PDC and 5 of 5 SRC and Buc et al. showed 5 out of 5 PDC stained with GCC.\textsuperscript{10,11} In contrast to the studies described above our study included a larger cohort of
PDCs and also included the specific poorly differentiated subtypes: MC, SRC and NE. Our results indicate that a significant percentage of PDC (25%) and MC (53%) are negative for GCC expression as compared to well differentiated CRC. Interestingly, 90% of the SRC cases stained for both markers. There was also a strong positive correlation between CDX2 and GCC expression. This was not surprising as intestinal GCC expression requires a CDX2 binding element in the proximal promoter of CDX2.9

One of the most important factors in guiding treatment in patients with colorectal carcinoma is regional lymph node metastases.23 Detection of micrometastases has important clinical implications and may lead to more aggressive chemotherapeutic treatment; however traditional techniques may fail to detect a significant proportion of lymph node metastases in CRC and lead to under-staging.24,25 Several studies have demonstrated the effectiveness of molecular studies using reverse transcriptase PCR for GCC in detecting occult micrometastases to lymph nodes in CRCs.12-15 Schulz et al. showed quantitative RT-PCR could be employed as a highly sensitive and specific method of detecting lymph node metastases.14 Carrithers et al also showed that by reverse transcriptase PCR GCC was present in peripheral blood samples of all patients with metastatic colorectal cancer and none of the control group and that the presence of GCC in peripheral blood samples may correlate with increased risk of recurrence or poorer prognosis.15 Bustin et al found that only 1/21 healthy patients had reverse transcriptase PCR positivity for GCC in the peripheral blood while 20/27 peri-operative patients with CRC were positive. In the same study CK19 and CK20, two markers typically positive in CRC, were found to be unreliable as indicators of circulating CRC tumors cells.6 Buc et al. also proposed GCC as a potential target for delivering chemotherapeutic agents directly to tumor cells by
binding heat stable enterotoxin to an chemotherapeutic protein with subsequent GCC
dependant tumor cell uptake.\textsuperscript{10}

Our findings suggest that if the primary CRC is poorly differentiated, there is a
significant chance that the lesion would not express GCC and thus metastases to lymph
nodes or circulating tumor cells in the peripheral blood may not be detected by molecular
methods. This would also be of significance if future modalities utilize GCC as a target
for delivery of proteins directly to tumor cells for imaging or chemotherapeutic purposes,
as PDC or poorly differentiated components of well differentiated CRC might not express
GCC.

Finally, the observation that a significant portion of these PDCs and poorly differentiated
components of well or moderately differentiated CRCs may lack staining with GCC is an
important consideration when using this immunohistochemical marker to aide in
determining the primary site in a metastatic carcinoma of unknown origin.

**Disclosure/Conflict of Interest**

S.A. Waldman is a paid consultant for Merck Research Laboratories and is the Chair
(uncompensated) of the Scientific Advisory Board for Targeted Diagnostics &
Therapeutics, Inc, which sponsors research and has a licence to commercialize diagnostic
and therapeutic products related to guanylyl cyclase C.
References


**Fig. 1.** Hematoxylin and eosin stains of poorly differentiated adenocarcinoma (A), medullary carcinoma (B), signet ring cell carcinoma (C) and neuroendocrine carcinoma (D) (original magnification x200).

**Fig. 2.** GCC staining pattern in normal colonic mucosa (A), well differentiated adenocarcinoma (B), poorly differentiated adenocarcinoma (C), medullary carcinoma (D), signet ring cell carcinoma (E), and neuroendocrine carcinoma (F) (original magnification x400).

**Fig. 3.** GCC staining in a whole section of tumor displaying both well differentiated (right) and poorly differentiated areas (left) (original magnification x40).